How do you approach a young patient with undifferentiated pleomorphic sarcoma of the upper extremity who developed ifosfamide-induced nephrotoxicity after two cycles of adjuvant AIM chemotherapy?

In the adjuvant setting, I would suggest to stop further therapy and observe the patient. There is no clear survival benefit with the use of adjuvant therapy. However, I do say this with the knowledge that Sarculator-based analysis of EORTC-STBSG 62931 has demonstrated an OS benefit in patients rece...

If the treatment is strictly adjuvant, OK to stop the chemotherapy. Might consider radiotherapy if not done pre-op.